Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Other financing activities (2020 - 2023)

NeuroPace's quarterly Other financing activities came in at $186000.0 in Q4 2023, down 46.4% year-on-year from $347000.0 in Q4 2022, and up 1966.67% quarter-over-quarter from $9000.0 in Q2 2023.

NeuroPace has reported Other financing activities for 4 years, with the latest figure at $186000.0 in Q4 2023.

  • For the quarter ending Q4 2023, Other financing activities fell 46.4% year-over-year to $186000.0; the trailing twelve-month figure through Sep 2024 stood at $186000.0 (down 60.09% YoY), and the FY2023 full-year result was $305000.0, down 12.1% from the prior year.
  • Other financing activities for Q4 2023 stood at $186000.0, up from $9000.0 in the prior quarter.
  • The five-year high for Other financing activities was $1.8 million in Q2 2021, with the low at $9000.0 in Q2 2023.
  • Average Other financing activities over 4 years is $554888.9, with a median of $186000.0 recorded in 2023.
  • Year-over-year, Other financing activities jumped 1447.01% in 2021 and slumped 46.4% in 2023.
  • Tracing NPCE's Other financing activities over 4 years: stood at $96000.0 in 2020, then jumped by 1785.42% to $1.8 million in 2021, then tumbled by 80.83% to $347000.0 in 2022, then tumbled by 46.4% to $186000.0 in 2023.
  • The last three Other financing activities figures came in at $186000.0 (Q4 2023), $9000.0 (Q2 2023), and $110000.0 (Q1 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 NeuroPace 558.86 Mn 504.88 Mn 18.05 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 186,000.00
Dec 31, 2023 186,000.00
Jun 30, 2023 9,000.00
Jun 30, 2023 9,000.00
Mar 31, 2023 110,000.00
Mar 31, 2023 110,000.00
Dec 31, 2022 347,000.00
Dec 31, 2022 347,000.00
Jun 30, 2021 1.81 Mn
Jun 30, 2021 1.81 Mn
Mar 31, 2021 1.58 Mn
Mar 31, 2021 1.58 Mn
Dec 31, 2020 96,000.00
Dec 31, 2020 96,000.00
Sep 30, 2020 737,000.00
Sep 30, 2020 737,000.00
Jun 30, 2020 117,000.00
Jun 30, 2020 117,000.00